Hasten acquires commercial rights in China for Roche's Antibiotic Rocephin®

On May 4, 2023, Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Under the agreement, Hasten acquired Roche’s China mainland rights for Rocephin®, including the product’s Marketing Authorization, Intellectual Property, trademarks, and technology transfer. Hasten is an investment of CBC Group, Asia's largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.

Lenz & Staehelin advised Hasten in this transaction. The team included Tino Gaberthüel and Lukas Held (both M&A), Peter Ling (IP) and Leo Rusterholz (Transitional Services).

Published: 8 May 2023